Desvenlafaxine
Khedezla, Pristiq (desvenlafaxine) is a small molecule pharmaceutical. Desvenlafaxine was first approved as Pristiq on 2008-02-29. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter and sodium-dependent serotonin transporter. In addition, it is known to target sodium-dependent dopamine transporter.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Trade Name
FDA
EMA
Pristiq (generic drugs available since 2015-06-29, discontinued: Khedezla)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
desvenlafaxine | ANDA | 2023-06-15 |
pristiq | New Drug Application | 2022-03-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
major depressive disorder | EFO_0003761 | D003865 | F22 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Desvenlafaxine Succinate, Pristiq, Pf Prism Cv | |||
8269040 | 2027-07-05 | DP |
HCPCS
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | 6 | 2 | 19 | 7 | 4 | 37 |
Depression | D003863 | F33.9 | — | 1 | 5 | 2 | 1 | 9 | |
Hot flashes | D019584 | 2 | — | 3 | 1 | 1 | 7 | ||
Pharmacokinetics | D010599 | — | — | — | 2 | — | 2 | ||
Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | — | — | — | 1 | 1 | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | — | 1 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | 1 | — | 1 |
Anhedonia | D059445 | R45.84 | — | — | — | 1 | — | 1 | |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | 1 | — | 1 |
Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 3 | — | 1 | — | — | 4 | ||
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 2 | 1 | — | — | 3 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 3 | — | — | 3 |
Diabetic neuropathies | D003929 | EFO_1000783 | 1 | — | 1 | — | — | 2 | |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | — | — | 1 |
Neoplasms | D009369 | C80 | — | 1 | 1 | — | — | 1 | |
Menopause | D008593 | EFO_0003922 | N95 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DESVENLAFAXINE |
INN | desvenlafaxine |
Description | O-desmethylvenlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine. It has a role as a marine xenobiotic metabolite, a drug metabolite and an antidepressant. It is a member of cyclohexanols, a member of phenols and a tertiary amino compound. |
Classification | Small molecule |
Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1 |
Identifiers
PDB | — |
CAS-ID | 93413-62-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1118 |
ChEBI ID | 83527 |
PubChem CID | 125017 |
DrugBank | DB06700 |
UNII ID | NG99554ANW (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Variants
Clinical Variant
No data
Financial
Pristiq - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,583 documents
View more details
Safety
Black-box Warning
Black-box warning for: Desvenlafaxine, Pristiq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
112,485 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more